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Abstract
 .To define the structural and chemical criteria governing recognition of oxidized LDL oxLDL by mouse peritoneal
 .macrophages MPM , we exposed LDL to novel chemical modification agents that induce defined neutralizing and
non-neutralizing alterations of lysine as models for distinct apoB adducts present in oxLDL. We found some exceptions to
the usual notion that neutralization of lysine positive charges is the principal determinant governing MPM recognition. In
addition, competitive binding experiments using chemically modified 125I-LDL preparations revealed that, whereas some
 .modifications engendered recognition principally by the classical scavenger receptor class A SRA , as seen for acetylated
 .LDL acLDL , chemical models of advanced aldehydic modifications of LDL led instead to MPM uptake mainly by oxLDL
receptors distinct from SRA. q 1997 Elsevier Science B.V.
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 .Oxidation of low density lipoprotein LDL has
been implicated in the pathogenesis of atherosclerosis
w x1,2 . The link is based on the observation that oxi-
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 .dized LDL oxLDL is internalized by a class of high
affinity receptors on macrophages that include the
 .scavenger receptor class A type Irtype II SRA
w x3–6 which is not downregulated by the intracellular
levels of cholesterol, and therefore leads to lipid
wloading of such macrophages called foam cells 1–
x3,6 . Such cells are present in the intima of large
arteries and constitute the characteristic of the fatty
w xstreak lesion 7 . The prototypic modification leading
to SRA recognition is acylation e.g., acetylation,
. w xmaleylation, succinylation 3,5,8 or carbamylation
w x9 , which induce large increases in the relative elec-
 .trophoretic mobility REM of the LDL particles on
w xaccount of neutralization of lysines 5,10 . By con-
trast, reductive methylation, which leaves the LDL
w xlysine charge unaffected 11 , results in little change
w xin REM and no significant SRA recognition 3 . It
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was concluded from these earlier studies that receptor
recognition reflects mainly the increase in surface
negative charge induced by neutralization of posi-
tively charged lysine «-amino groups. However, these
prototypic modifications may not be particularly rele-
vant to chemical changes that occur physiologically
w xin oxLDL 5 , and, especially for acylation, may
reflect modification of lipoprotein nucleophiles dis-
tinct from apoB lysines.
The key modifications present in oxLDL responsi-
ble for macrophage receptor recognition are those
induced on apoB lysines by the variety of reactive
aldehydes generated during peroxidation of LDL
w x  .lipids 1,2,5,10 . 4-Hydroxy-2-nonenal HNE adducts
w xpresent in oxLDL 12 are thought to be a major actor
w x w xin cytotoxicity 10,13 and lipid loading 14 , though
 .modifications by malondialdehyde MDA as well as
w xby a ,b-unsaturated aldehydes 15,16 and 3,4-epoxy-
w x2-enals 17 are likely to contribute to the functional
properties of oxLDL. Definition of the chemical
 .type s of modification most responsible for
macrophage uptake of LDL treated with HNE or
MDA has not been possible, however, because these
aldehydes induce a heterogeneous array of lysine
w xmodifications 5,10,18 : MDA can form neutral dihy-
dropyridine adducts, simple lysine enaminones, and
w xenaminoimine lysine–lysine crosslinks 8,10,19 ,
whereas HNE can form both Schiff base and Michael
adducts initially, followed by several possible sec-
ondary reactions reflecting condensative, dehydrative,
wand oxidative maturing of the initial adducts 10,20–
x23 . Since all these adducts are physicochemically
quite distinct from acylation and carbamylation, they
might thus lead to receptor recognition in ways not
w xseen in previous studies 4,5,8 . We have therefore
investigated LDL derivatization by selected lysine
 .group-specific reagents see Scheme 1 as models for
several different general types of apoB modification
suspected in physiological oxLDL that cannot them-
selves be generated homogeneously by direct treat-
ment with any of the lipid-derived aldehydes so far
identified.
With the exception of 4-oxononanal, synthesized
w xas described elsewhere 22 , chemical reagents were
used as obtained commercially. Lipoprotein-deficient
 .serum LPDS and LDL were isolated, LDL was
 125 .labelled with Na I and oxidized, and protein was
w xdetermined as described elsewhere 24 . Acetylation
of LDL was performed by repeated additions of
w xacetic anhydride 3 . Carbamylation of LDL was
w xachieved by incubation with potassium cyanate 11 .
Malondialdehyde modification of LDL was per-
w xformed as described by Haberland et al. 8 . Novel
modifications of 125I-LDL were conducted at 378C in
0.1 M borate buffer with the chemical reagents se-
lected on the basis of their ability to induce the lysine
modifications shown in Scheme 1. Since the different
agents possessed different reactivities, we initially
carried out modifications at several concentrations,
pH values, and time intervals. For comparison pur-
poses, we selected representative treatments required
 .to induce moderate 31–54% modification of lysyl
 .residues see Table 1 as determined using the 2,4,6-
 .trinitrobenzenesulfonic acid TNBS colorimetric as-
w xsay 25 . These conditions were: 100 mM 2,4-penta-
 .nedione for 21 h pdLDL , 100 mM acrylonitrile for
 .21 h anLDL , 200 mM 2,5-hexanedione for 48 h
 .  .hdLDL , and 0.5 mM 4-oxononanal for 4 h onaLDL
Scheme 1. Chemical modifications that model types of adduction
chemistry likely to occur as a result of oxidative modification of
 .LDL see text for details .
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Table 1
Extent of modification of LDL and recognition by MPM
Modified LDL Lysine blocked REM Degradation Association
 .  .  .  .% relative to LDL mgrmg cell protein mgrmg cell protein
125I-LDL 0 1.0 0.49"0.05 0.17"0.07
125I-acLDL 38 4.0 8.77"0.73 1.23"0.10
125I-cmLDL 34 4.0 11.05"1.80 0.95"0.26
125I-mdaLDL 50 4.0 6.68"0.43 0.86"0.02
125I-pdLDL 51 2.7 3.46"0.08 0.34"0.02
125I-tmpLDL 48 1.2 7.48"0.52 1.26"0.17
125I-anLDL 47 2.6 1.02"0.02 0.36"0.02
125I-hdLDL 31 1.9 10.13"0.34 1.23"0.09
125I-onaLDL 54 2.2 10.73"0.16 1.83"0.02
125  .  .  .  .Aliquots of I-LDL 500 mgrml were subjected to acetylation acLDL , carbamylation cmLDL , MDA treatment mdaLDL , as
w x  .  .  .described elsewhere 3,8,11 , or treated with 2,4-pentanedione pdLDL , 2,4,6-trimethylpyrylium tmpLDL , acrylonitrile anLDL ,
 .  . w x w x2,5-hexanedione hdLDL , or 4-oxononanal onaLDL as described in the text. Lysine blockage 25 and REM 18 were measured as
described previously. Macrophage recognition was assessed by incubating cultures of MPM for 5 h at 378C in RPMI-1640 medium
125  .containing 10% LPDS, and one of the modified forms of I-LDL 10 mgrml , followed by measuring cell-degraded and cell-associated
125I-lipoprotein as described in the text.
at pH 8.0, and 20 mM 2,4,6-trimethylpyrylium for 4
 .h at pH 8.5 tmpLDL . At the end of each modifica-
tion procedure, modified forms of LDL were exten-
sively dialyzed against PBS containing 0.3 mM
EDTA, centrifuged for 30 min at 10,000=g, and
passed through a 0.22 mm filter. The electrophoretic
 . w xmobility relative to LDL REM was determined 18
as an indirect measure of the change in charge on the
LDL particle as a consequence of lysine modifica-
tion.
The modified LDL preparations were then incu-
bated with thioglycollate-elicited mouse peritoneal
macrophages to determine cell association and degra-
dation values by the procedures described elsewhere
w x26,27 . In brief, cells were washed with PBS and the
indicated concentrations of 125I-ligands were added
for 5 h in media containing 10% LPDS. The media
were then removed and assayed for trichloroacetic
 .acid TCA -soluble, non-iodine degradation products
w xas described previously 26 . Cells were washed three
times with PBS, dissolved in 0.1 N NaOH, and
assayed for cell-associated label and protein content.
Total uptake was calculated from the sum of degrada-
tion and cell-associated label. All determinations are
reported as mean"S.D. of triplicate determinations.
Three modifications of LDL which neutralize ly-
 .sine charge, acetylation acLDL , carbamylation
 .  .cmLDL , and MDA treatment mdaLDL , resulted
in large increases in REM and substantial uptakerde-
 .gradation Table 1 , consistent with earlier reports
w x3,8,9,18 . Since MDA modification includes dihy-
dropyridines and enaminoimine crosslinks as well as
Schiff base-derived enaminones, we used 2,4-penta-
 .nedione pdLDL , the diketone analog of MDA
known to produce only the latter Scheme 1, Ref.
w x.28 , as our model of simple Schiff base adduction.
Interestingly, this neutralizing modification was asso-
ciated with only modest increases in REM and levels
 .of uptakerdegradation by MPM Table 1 .
 .Acrylonitrile modification of LDL anLDL was
w xused as a model for the Michael type adducts 29
w xformed between lysine and lipid derived 2-enals 30
and 4-hydroxy-2-enals which decrease the nitrogen
pK , thereby increasing the degree of neutralizationa
 .at physiological pH Scheme 1 . Modification by
acrylonitrile to an extent of 47% blockage of apoB
lysines, resulted in an increased REM, consistent
with at least partial lysine neutralization, but only a
marginal level of uptake and degradation by MPM
 .Table 1 . These findings suggest that Michael adducts
do not contribute significantly to uptake of oxLDL by
macrophages. This is one example in which charge
neutralization does not guarantee significant binding
and uptake by macrophages.
Reductive methylation of LDL lysines is a non-
neutralizing modification that fails to induce recogni-
w xtion by scavenger receptors 3 . To ascertain the
generality of this finding, we modified LDL with
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 .2,4,6-trimethylpyrylium tmpLDL , which converts
the lysine «-amino group to a pyridinium group with
w x  .retention of the positive charge 31 Scheme 1 . The
pyridinium adduct served as a model for the nucleus
of crosslinks possibly resulting from multistep con-
densationrdehydration chemistries following initial
Schiff base modification by bifunctional aldehydes
w xsuch as HNE and MDA 10,32,33 , similar to what
occurs following lysyl oxidase treatment of lysine-rich
w xproteins such as collagen 34 . Evidence that such
adducts may be present in oxLDL is the characteristic
w xfluorescence exhibited by atherosclerotic plaques 35
that is also seen in oxLDL at higher oxidation levels
w x10,13 and upon extended treatment of LDL with
w xHNE 13,14 . Consistent with the expected chemical
w xchange 31 , 2,4,6-trimethylpyrylium modification led
to significant blockage of lysyl residues on apoB
without significant changes in REM. Unlike reductive
methylation, however, tmpLDL induced significant
 .levels of uptake and degradation by MPM Table 1 .
Thus, it does not appear that the lack of receptor
recognition accompanying reductive methylation is
paralleled by all lysine modifications which retain the
charge.
A further novel modification of LDL reported in
this study involves g-dicarbonyl reagents which con-
vert the lysine amino groups to neutral pyrroles
w x  .21,36 . 2,5-Hexanedione hdLDL forms a 2,5-di-
 .methylpyrrole, while 4-oxononanal onLDL forms
 .the same 2-pentylpyrrole Scheme 1 that we showed
previously to represent a minor, yet important late-
stage stable adduct that arises when proteins are
w xtreated with HNE 37 . We refer to the 2-pentylpyr-
role as an ‘advanced lipid peroxidation end product’
 .ALE , analogous to advanced glycation end product
 .AGE modifications. Achieving similar levels of
lysine modification required higher concentrations of
the diketone 2,5-hexanedione than the ketoaldehyde
 .4-oxononanal see Section 2 , which was anticipated
on the basis of their relative chemical reactivities
w x38 . Nonetheless, at roughly equivalent levels of
modification, practically identical levels of uptake
and degradation were induced by either reagent Ta-
.ble 1 . This result is consistent with the hypothesis
that 2-pentylpyrrole formation in HNE-modified LDL
may be a key contributor to macrophage uptake and
degradation of oxLDL. Based on the modest amounts
needed to induce high values of degradation, 4-
oxononanal appears to be the most potent reagent
inducing macrophage recognition of LDL so far re-
ported, with perhaps the exception of a structurally
related modification induced by the oxidative product
w xof arachidonic acid, levuglandin 39 .
Based on the data presented in Table 1, those
modifications that demonstrated enhanced internaliza-
tion and processing by MPM were subsequently sub-
jected to competition studies to ascertain whether
w xthey were recognized by the SRA 6 andror via
 .some other receptor s , previously documented to
w xrecognize oxLDL 4,40 . As seen in Fig. 1, degrada-
Fig. 1. Competition by excess amounts of unlabeled acLDL or oxLDL for the degradation of modified 125I-LDL by MPM. Each well of a
125  .24-well plate received 250 ml of RPMI-1640 medium containing 10% LPDS, and one of the modified forms of I-LDL 10 mgrml in
 .the presence or absence of a 30-fold excess of unlabeled acLDL or oxLDL 300 mgrml . After incubation for 5 h at 378C, the amounts of
degradation were determined as described in the text.
( )G. Hoppe et al.rBiochimica et Biophysica Acta 1362 1997 103–108 107
tion of 125I-labelled acLDL, mdaLDL, or cmLDL
was essentially completely inhibited by a 30-fold
excess of both unlabelled acLDL and oxLDL, consis-
w xtent with published results 3,8,9 . Excess amounts of
unlabelled oxLDL and, for the most part, unlabelled
acLDL also competed for the degradation of 125I-
pdLDL. The results for cell association of these
modified forms of LDL at 378C mirrored the results
on degradation but were about one order of magni-
 .tude lower not shown . That both excess acLDL and
oxLDL effectively competed for degradation of 125I-
labelled pdLDL, acLDL, mdaLDL, or cmLDL, is
consistent with the recognition of all these neutraliz-
w xing modifications by the SRA 3,8 . By contrast,
degradation and cell association of 125I-LDL modi-
fied by the two pyrrolylating agents, 2,5-hexanedione
and 4-oxononanal, and of the charge-retaining pyri-
dinium modifier, 2,4,6-trimethylpyrylium, was
blocked by excess oxLDL, but reduced only slightly
 .  .20% by excess acLDL Fig. 1 . These particular
 .modified LDLs thus appear to share binding site s
on MPM predominantly with oxLDL, but only slightly
with acLDL.
Since we previously showed that oxLDL can sig-
w xnificantly inhibit lysosomal proteolysis 24,27 , we
felt it was necessary to assess whether enzyme inacti-
vation was a potential cause of the uniform inhibition
of degradation of the various modified 125I-LDL
preparations by oxLDL. We therefore determined the
cell association of representative modified LDL
preparations at 48C, which reflects macrophage recep-
tor binding in the absence of any uptake processes.
We found that binding at 48C of hdLDL and tmpLDL
was similarly blocked by oxLDL, but only slightly by
 .acLDL Fig. 2 . As this is consistent with results on
degradation at 378C, it is unlikely that the competi-
tion seen for degradation of modified LDL by oxLDL
was due to lysosomal enzyme inactivation. In further
control studies performed using non-lipoprotein 125I-
ligands, we verified that oxLDL was not exerting a
non-specific effect on all cell receptors Hoppe et al.,
.unpublished studies . Collectively, these results sup-
port our conclusion that uptakerprocessing of the
pyrrole- and pyridinium-bearing-LDLs is mediated
w xlargely by an oxLDL-receptor 4 distinct from SRA
w x6 .
In conclusion, our goal in this study was to evalu-
ate uptake of oxLDL by macrophages using chemical
Fig. 2. Competition of excess amounts of unlabeled acLDL and
oxLDL for the binding at 48C of modified 125I-LDL to MPM.
Each well of a 24-well plate received 250 ml of RPMI-1640
medium containing 10% LPDS, 20 mM HEPES, and 125I-acLDL,
125I-hdLDL, or 125I-tmpLDL at 10 mgrml, in the presence or
absence of a 30-fold excess of unlabeled acLDL or oxLDL 300
.mgrml . After incubation for 2 h at 48C, the amount of cell-asso-
ciated 125I-lipoprotein was determined as described in the text.
modifiers which might be more relevant than acyla-
tion to chemical changes expected on oxLDL as a
result of lysine derivatization by lipid peroxidation
products. The ability of excess amounts of oxLDL
but not of acLDL to compete maximally for binding,
internalization, and degradation of onaLDL, hdLDL,
or tmpLDL in MPM, suggests that the major contri-
bution of recognition of these modified forms of LDL
is by a receptor different from the SRA, but one
recognizing oxLDL. In the case of onaLDL and
hdLDL, the conversion of LDL lysines to pyrroles
must thus alter the physicochemical behavior of the
 .LDL particle presumably its surface in a manner
distinct from that induced by classical neutralizing
modifications which require only recognition by the
SRA. In the case of tmpLDL, the pyridinium adduct
must alter some feature perhaps conformational
.andror local dielectric changes on the lipoprotein,
despite the fact that overall charge is retained in the
same manner as for lysine methylation. Substantial
current evidence now exists for classes of oxLDL
w x w xreceptors such as CD36 41 and CD68 4 that are
distinct from the SRA. Our results represent the first
clues to the structural nature of the types of lipid-de-
rived modifications present on apoB lysines that en-
gender recognition by non-SRA receptors. Although
the charge neutralization hypothesis may define re-
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quirements for ligand recognition by the SRA, other
rules may apply for recognition by alternate receptors
for oxLDL. The modified LDL preparations reported
here may serve as valuable ligands for molecular
characterization of these novel receptor classes and
their mechanisms of operation.
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